Pantecta Control

RSS

Withdrawn

This medicine's authorisation has been withdrawn

pantoprazole
MedicineHumanWithdrawn

Slovak is available via eTranslation, the European Commission's machine translation service.

Translate to Slovak | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 19 September 2016, the European Commission withdrew the marketing authorisation for Pantecta Control (pantoprazole) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Takeda GmbH, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. 

Pantecta Control was granted marketing authorisation in the EU as an over-the-counter product on 12 June 2009 for the treatment of reflux symptoms (e.g. heartburn, acid regurgitation). The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2014. 

Pantecta Control was a duplicate application to Pantozol Control 20 mg gastro-resistant tablets, which is marketed in several EU countries. The marketing authorisation holder will maintain the marketing authorisation for Pantozol Control 20 mg gastro-resistant tablets and the remaining duplicates Controloc Control 20 mg gastro-resistant tablets, Somac Control 20 mg gastro-resistant tablets and Pantoloc Control 20 mg gastro-resistant tablets. 

The European Public Assessment Report (EPAR) for Pantecta Control is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

български (BG) (584.48 KB - PDF)

Zobraziť

español (ES) (512.81 KB - PDF)

Zobraziť

čeština (CS) (576.89 KB - PDF)

Zobraziť

dansk (DA) (512.5 KB - PDF)

Zobraziť

Deutsch (DE) (513.99 KB - PDF)

Zobraziť

eesti (ET) (513.31 KB - PDF)

Zobraziť

ελληνικά (EL) (584.2 KB - PDF)

Zobraziť

français (FR) (514.66 KB - PDF)

Zobraziť

italiano (IT) (536.62 KB - PDF)

Zobraziť

latviešu (LV) (552.19 KB - PDF)

Zobraziť

lietuvių (LT) (558.54 KB - PDF)

Zobraziť

magyar (HU) (549.7 KB - PDF)

Zobraziť

Malti (MT) (555.41 KB - PDF)

Zobraziť

Nederlands (NL) (512.93 KB - PDF)

Zobraziť

polski (PL) (577.87 KB - PDF)

Zobraziť

português (PT) (513.19 KB - PDF)

Zobraziť

română (RO) (559.28 KB - PDF)

Zobraziť

slovenčina (SK) (576.32 KB - PDF)

Zobraziť

slovenščina (SL) (566.92 KB - PDF)

Zobraziť

suomi (FI) (513 KB - PDF)

Zobraziť

svenska (SV) (535.02 KB - PDF)

Zobraziť

Product information

български (BG) (1.01 MB - PDF)

Zobraziť

español (ES) (703.94 KB - PDF)

Zobraziť

čeština (CS) (830.86 KB - PDF)

Zobraziť

dansk (DA) (779.67 KB - PDF)

Zobraziť

Deutsch (DE) (747.37 KB - PDF)

Zobraziť

eesti (ET) (710.15 KB - PDF)

Zobraziť

ελληνικά (EL) (855.12 KB - PDF)

Zobraziť

français (FR) (1.06 MB - PDF)

Zobraziť

hrvatski (HR) (875.24 KB - PDF)

Zobraziť

italiano (IT) (846.87 KB - PDF)

Zobraziť

latviešu (LV) (919.86 KB - PDF)

Zobraziť

lietuvių (LT) (844.2 KB - PDF)

Zobraziť

magyar (HU) (955.3 KB - PDF)

Zobraziť

Malti (MT) (884.2 KB - PDF)

Zobraziť

Nederlands (NL) (712.71 KB - PDF)

Zobraziť

polski (PL) (838.71 KB - PDF)

Zobraziť

português (PT) (752.54 KB - PDF)

Zobraziť

română (RO) (787.92 KB - PDF)

Zobraziť

slovenčina (SK) (1.01 MB - PDF)

Zobraziť

slovenščina (SL) (900.92 KB - PDF)

Zobraziť

suomi (FI) (729.76 KB - PDF)

Zobraziť

svenska (SV) (776.59 KB - PDF)

Zobraziť

Íslenska (IS) (812.57 KB - PDF)

Zobraziť

norsk (NO) (691.29 KB - PDF)

Zobraziť
Latest procedure affecting product information:IG/0634
19/09/2016
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (520.33 KB - PDF)

Zobraziť

español (ES) (460 KB - PDF)

Zobraziť

čeština (CS) (485.81 KB - PDF)

Zobraziť

dansk (DA) (12.5 KB - PDF)

Zobraziť

Deutsch (DE) (459.21 KB - PDF)

Zobraziť

eesti (ET) (459.66 KB - PDF)

Zobraziť

ελληνικά (EL) (517.23 KB - PDF)

Zobraziť

français (FR) (459.89 KB - PDF)

Zobraziť

italiano (IT) (459.36 KB - PDF)

Zobraziť

latviešu (LV) (515.05 KB - PDF)

Zobraziť

lietuvių (LT) (503.17 KB - PDF)

Zobraziť

magyar (HU) (504.28 KB - PDF)

Zobraziť

Malti (MT) (511.13 KB - PDF)

Zobraziť

Nederlands (NL) (459.79 KB - PDF)

Zobraziť

polski (PL) (508 KB - PDF)

Zobraziť

português (PT) (459.34 KB - PDF)

Zobraziť

română (RO) (490.38 KB - PDF)

Zobraziť

slovenčina (SK) (487.09 KB - PDF)

Zobraziť

slovenščina (SL) (471.21 KB - PDF)

Zobraziť

suomi (FI) (459.07 KB - PDF)

Zobraziť

svenska (SV) (459.85 KB - PDF)

Zobraziť

Product details

Name of medicine
Pantecta Control
Active substance
pantoprazole
International non-proprietary name (INN) or common name
pantoprazole
Therapeutic area (MeSH)
Gastroesophageal Reflux
Anatomical therapeutic chemical (ATC) code
A02BC02

Pharmacotherapeutic group

Proton pump inhibitors

Therapeutic indication

Short-term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults.

Authorisation details

EMA product number
EMEA/H/C/001099
Marketing authorisation holder
Takeda GmbH

Byk-Gulden-Strasse 2
D-78467 Konstanz
Germany

Marketing authorisation issued
12/06/2009
Withdrawal of marketing authorisation
19/09/2016
Revision
7

Assessment history

This page was last updated on

Share this page